In conclusion, we profiled ZFX binding sites genome-wide in kidney, colon, prostate, and breast cancer cells and found that ZFX may function as a transcriptional activator, regulating as many as 60% of active CpG island promoters. This evidence concerns the gene ZFX and breast cancer.